Anti-müllerian Hormone and Its Clinical Use in Pediatrics with Special Emphasis on Disorders of Sex Development

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2013 Dec 25

PMID 24367377

Citations 31

Authors

Marie Lindhardt Johansen

Casper P Hagen

Trine Holm Johannsen

Katharina M Main

Jean-Yves Picard

Anne Jorgensen

Ewa Rajpert-De Meyts

Anders Juul

Affiliations

Soon will be listed here.

Abstract

Using measurements of circulating anti-Müllerian hormone (AMH) in diagnosing and managing reproductive disorders in pediatric patients requires thorough knowledge on normative values according to age and gender. We provide age- and sex-specific reference ranges for the Immunotech assay and conversion factors for the DSL and Generation II assays. With this tool in hand, the pediatrician can use serum concentrations of AMH when determining the presence of testicular tissue in patients with bilaterally absent testes or more severe Disorders of Sex Development (DSD). Furthermore, AMH can be used as a marker of premature ovarian insufficiency (POI) in both Turner Syndrome patients and in girls with cancer after treatment with alkylating gonadotoxic agents. Lastly, its usefulness has been proposed in the diagnosis of polycystic ovarian syndrome (PCOS) and ovarian granulosa cell tumors and in the evaluation of patients with hypogonadotropic hypogonadism.

Citing Articles

Clinical utility of anti-Müllerian hormone in female children and adolescents.

Birbas E, Vatopoulou A, Kanavos T, Birmpas K, Skentou C, Zikopoulos A Hormones (Athens). 2024; .

PMID: 39477856 DOI: 10.1007/s42000-024-00603-5.

Analytical performances of a novel fluorescent immunoassay of anti-Müllerian hormone and establishment of the reference intervals in Chinese children.

Li L, Li M, Zhu W, Shen L, Jiang L Pract Lab Med. 2024; 41:e00419.

PMID: 39205827 PMC: 11350448. DOI: 10.1016/j.plabm.2024.e00419.

Serum anti-Mullerian hormone levels in Turkish girls aged 18 and younger for ovarian reserve determination.

Ozcivit Erkan I, Oncul M, Basibuyuk Z, Cebi C, Cepni I J Turk Ger Gynecol Assoc. 2024; 25(3):138-143.

PMID: 38775713 PMC: 11576653. DOI: 10.4274/jtgga.galenos.2024.2023-8-5.

Reference Ranges of Serum Anti-Müllerian Hormone in Healthy Reproductive-aged Omani Women.

Al Risi E, Zadjali F, Mula-Abed W Oman Med J. 2023; 38(3):e508.

PMID: 37476475 PMC: 10354694. DOI: 10.5001/omj.2023.79.

AMH and other markers of ovarian function in patients with Turner syndrome - a single center experience of transition from pediatric to gynecological follow up.

Hagen C, Fischer M, Mola G, Mikkelsen T, Cleemann L, Gravholt C Front Endocrinol (Lausanne). 2023; 14:1173600.

PMID: 37455919 PMC: 10339808. DOI: 10.3389/fendo.2023.1173600.

References

Rey R . Endocrine, paracrine and cellular regulation of postnatal anti-müllerian hormone secretion by sertoli cells. Trends Endocrinol Metab. 2008; 9(7):271-6. DOI: 10.1016/s1043-2760(98)00069-1. View

Nelson S, La Marca A . The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online. 2011; 23(4):411-20. DOI: 10.1016/j.rbmo.2011.06.011. View

Lie Fong S, Visser J, Welt C, de Rijke Y, Eijkemans M, Broekmans F . Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012; 97(12):4650-5. PMC: 3683801. DOI: 10.1210/jc.2012-1440. View

Grinspon R, Loreti N, Braslavsky D, Bedecarras P, Ambao V, Gottlieb S . Sertoli cell markers in the diagnosis of paediatric male hypogonadism. J Pediatr Endocrinol Metab. 2012; 25(1-2):3-11. DOI: 10.1515/jpem-2011-0453. View

Guibourdenche J, Lucidarme N, Chevenne D, Rigal O, Nicolas M, Luton D . Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical interest. Mol Cell Endocrinol. 2003; 211(1-2):55-63. DOI: 10.1016/j.mce.2003.09.011. View

Schumer S, Cannistra S . Granulosa cell tumor of the ovary. J Clin Oncol. 2003; 21(6):1180-9. DOI: 10.1200/JCO.2003.10.019. View

Sir-Petermann T, Codner E, Maliqueo M, Echiburu B, Hitschfeld C, Crisosto N . Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91(8):3105-9. DOI: 10.1210/jc.2005-2693. View

Belville C, van Vlijmen H, Ehrenfels C, Pepinsky B, Rezaie A, Picard J . Mutations of the anti-mullerian hormone gene in patients with persistent mullerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol. 2003; 18(3):708-21. DOI: 10.1210/me.2003-0358. View

Grinspon R, Rey R . New perspectives in the diagnosis of pediatric male hypogonadism: the importance of AMH as a Sertoli cell marker. Arq Bras Endocrinol Metabol. 2012; 55(8):512-9. DOI: 10.1590/s0004-27302011000800003. View

10.

Gustafson M, Lee M, Scully R, Moncure A, Hirakawa T, Goodman A . Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med. 1992; 326(7):466-71. DOI: 10.1056/NEJM199202133260707. View

11.

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S . Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12):5957-62. DOI: 10.1210/jc.2003-030727. View

12.

Jorgensen A, Nielsen J, Blomberg Jensen M, Graem N, Rajpert-De Meyts E . Analysis of meiosis regulators in human gonads: a sexually dimorphic spatio-temporal expression pattern suggests involvement of DMRT1 in meiotic entry. Mol Hum Reprod. 2012; 18(11):523-34. DOI: 10.1093/molehr/gas030. View

13.

Fleming R, Nelson S . Reproducibility of AMH. Hum Reprod. 2012; 27(12):3639-41. DOI: 10.1093/humrep/des343. View

14.

Dewailly D, Gronier H, Poncelet E, ROBIN G, Leroy M, Pigny P . Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011; 26(11):3123-9. DOI: 10.1093/humrep/der297. View

15.

Silverman L, Gitelman S . Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. J Pediatr. 1996; 129(6):918-21. DOI: 10.1016/s0022-3476(96)70040-9. View

16.

Jamieson S, Fuller P . Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012; 33(1):109-44. DOI: 10.1210/er.2011-0014. View

17.

Baker M, Hutson J . Serum levels of mullerian inhibiting substance in boys throughout puberty and in the first two years of life. J Clin Endocrinol Metab. 1993; 76(1):245-7. DOI: 10.1210/jcem.76.1.8421093. View

18.

Sonmezer M, Ozmen B, Atabekoglu C, Papuccu E, Ozkavukcu S, Berker B . Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism. J Assist Reprod Genet. 2012; 29(7):597-602. PMC: 3401247. DOI: 10.1007/s10815-012-9759-1. View

19.

Aksglaede L, Sorensen K, Boas M, Mouritsen A, Hagen C, Jensen R . Changes in anti-Müllerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endocrinol Metab. 2010; 95(12):5357-64. DOI: 10.1210/jc.2010-1207. View

20.

Rey R, Louis F, Jaubert F, Barbet P, Nihoul-Fekete C, Chaussain J . Testicular dysgenesis does not affect expression of anti-müllerian hormone by Sertoli cells in premeiotic seminiferous tubules. Am J Pathol. 1996; 148(5):1689-98. PMC: 1861550. View